目的探讨局部晚期宫颈鳞癌(cervical squamous cell carcinoma,CSCC)患者外周血和癌组织中T细胞上表达B、T细胞弱化因子(B and T lymphocyte attenuator,BTLA)的差异,初步评价其与近期疗效的关系。方法收集新疆医科大学附属肿瘤医院2017...目的探讨局部晚期宫颈鳞癌(cervical squamous cell carcinoma,CSCC)患者外周血和癌组织中T细胞上表达B、T细胞弱化因子(B and T lymphocyte attenuator,BTLA)的差异,初步评价其与近期疗效的关系。方法收集新疆医科大学附属肿瘤医院2017年1-10月收治的45例CSCC患者,采用流式细胞术检测患者外周血和癌组织中T细胞上BTLA的表达量,并结合临床资料对比分析。结果局部晚期CSCC外周血中CD4+T细胞上BTLA的表达量(60.60%)高于CSCC组织(0.57%),其差异有统计学意义(P<0.001);CSCCBTLA外周血CD8+T细胞上的表达量(32.20%)高于CSCC组织(1.04%),其差异有统计学意义(P<0.001);结节型CSCC外周血CD8+T细胞BTLA的表达量(33.40%)高于菜花型(25.60%);低分化CSCC患者癌组织CD8+T细胞上BTLA的表达量(2.99%)高于中分化(0.72%),差异君有统计学意义(P=0.011,P=0.034);BTLA在有、无恶性肿瘤家族史的CSCC患者癌组织CD4+、CD8+T细胞上的分别为表达量(7.04%、6.96%、0.54%、0.99%),差异均有统计学意义(P<0.05)。结论BTLA在局部晚期CSCC患者癌组织T细胞上的表达低于外周血,提示应用抗BTLA治疗CSCC可能会导致机体产生较严重的全身免疫相关不良反应,推测BTLA可能不是CSCC免疫治疗的理想靶点。展开更多
Epidemiological studies have shown that human leukocyte antigen（HLA） allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma（NPC）, and in a previous study, we showed that HLA-B＊...Epidemiological studies have shown that human leukocyte antigen（HLA） allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma（NPC）, and in a previous study, we showed that HLA-B＊46 and HLA-A＊02-B＊46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival（LRFS）, distant metastasis-free survival（DMFS）, disease-free survival（DFS）, and overall survival（OS） were analyzed. The 5-year DMFS of the HLA-A＊02-B＊46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS（P=0.032, 0.040, and 0.013, respectively）. We found that the HLA-A＊02-B＊46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC.展开更多
文摘目的探讨局部晚期宫颈鳞癌(cervical squamous cell carcinoma,CSCC)患者外周血和癌组织中T细胞上表达B、T细胞弱化因子(B and T lymphocyte attenuator,BTLA)的差异,初步评价其与近期疗效的关系。方法收集新疆医科大学附属肿瘤医院2017年1-10月收治的45例CSCC患者,采用流式细胞术检测患者外周血和癌组织中T细胞上BTLA的表达量,并结合临床资料对比分析。结果局部晚期CSCC外周血中CD4+T细胞上BTLA的表达量(60.60%)高于CSCC组织(0.57%),其差异有统计学意义(P<0.001);CSCCBTLA外周血CD8+T细胞上的表达量(32.20%)高于CSCC组织(1.04%),其差异有统计学意义(P<0.001);结节型CSCC外周血CD8+T细胞BTLA的表达量(33.40%)高于菜花型(25.60%);低分化CSCC患者癌组织CD8+T细胞上BTLA的表达量(2.99%)高于中分化(0.72%),差异君有统计学意义(P=0.011,P=0.034);BTLA在有、无恶性肿瘤家族史的CSCC患者癌组织CD4+、CD8+T细胞上的分别为表达量(7.04%、6.96%、0.54%、0.99%),差异均有统计学意义(P<0.05)。结论BTLA在局部晚期CSCC患者癌组织T细胞上的表达低于外周血,提示应用抗BTLA治疗CSCC可能会导致机体产生较严重的全身免疫相关不良反应,推测BTLA可能不是CSCC免疫治疗的理想靶点。
基金supported by grants from the Chinese International Cooperation Project(No.2012DFA31560)Key Laboratory Projects of Xinjiang Uygur Autonomous Region(No.2015KL021)the Achievement Promotion Projects of the Autonomous Region(No.201554142)
文摘Epidemiological studies have shown that human leukocyte antigen（HLA） allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma（NPC）, and in a previous study, we showed that HLA-B＊46 and HLA-A＊02-B＊46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival（LRFS）, distant metastasis-free survival（DMFS）, disease-free survival（DFS）, and overall survival（OS） were analyzed. The 5-year DMFS of the HLA-A＊02-B＊46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS（P=0.032, 0.040, and 0.013, respectively）. We found that the HLA-A＊02-B＊46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC.
